Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China
Authors' conclusion
Treatment with OW SC semaglutide versus comparators was associated with increased proportions of participants with T2D meeting the composite metabolic endpoint.
Study context
- Population
- Adults (≥18 years) with T2D and HbA1c ≥7.0% (≥53 mmol/mol), randomized in SUSTAIN 1–5, 7–10 and SUSTAIN China
- Participants
- 7,633 adults10 trials
- Comparison
- Once-weekly (OW) subcutaneous (SC) semaglutide vs comparators
- Outcome
- Metabolic composite endpoint:
- HbA1c <7% (<53 mmol/mol)
- Blood pressure <140/90 mmHg
- Non-HDL cholesterol <130 mg/dl (<3.37 mmol/L)
Methodological detailspatient-level pooled data
- Patient-level pooled data
Pooled result
As reported in the abstract
Achieved metabolic composite endpoint
Semaglutide 0.5 mg vs Comparators: P < 0.0001 · Semaglutide 1.0 mg vs Comparators: P < 0.0001
Further pooled results
| Outcome | Comparators | P value |
|---|---|---|
| Achieved metabolic composite endpoint, semaglutide doses pooledSemaglutide pooled vs Comparators · significantly higher with semaglutide | 11.4% | P < 0.0001 |
- Achieved metabolic composite endpoint, semaglutide doses pooled: Semaglutide pooled 29.1%
Original publication
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China. Diabetes Obes Metab. Published 12 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →